Science News

... from universities, journals, and other research organizations

New Hope for Better Treatment of Psoriasis

Jan. 11, 2012 — Researchers at Linköping University are now launching a plan to effectively treat psoriasis. About 300 000 Swedes suffer from the difficult to treat disease, which manifests itself in scaly and often itchy patches on the skin. The reason is that cells divide without restraint as new blood vessels form in the deeper layers of the skin.


Share This:

An important component is the psoriasin protein

(S100A7), which are abundant in psoriasis-affected skin but rarely in normal skin. The same protein is also assumed to be a factor in the development of breast cancer. The research team, led by associate professor Charlotta Enerbäck, have now illustrated that, in a study on cultured skin cells, the interaction between psoriasin, oxygen free radicals and vascular endothelial growth factors (VEGF) leads to significantly increased cell division and growth of new blood vessels (angiogenesis). When we blocked the formation of psoriasin, the expression of VEGF also decreased.

Published in the journal Breast Cancer Research and Treatment, the results open new possibilities for the effective treatment of this crippling disease.

"We want to examine the ability of psoriasin as a target for therapy. By inhibiting psoriasin, we believe we can reduce vascular formation and thus the proliferation of the disease's magnitude and intensity," says Charlotta Enerbäck.

Previous studies in mice have shown that angiogenesis inhibitors reduce not only neovascularization but also inflammation and excessive cell division. Attempts to inhibit the growth factor VEGF have resulted in unwanted side effects because it exists in normal tissue where it contributes to wound healing.

"Since psoriasin expresses itself specifically only in the diseased psoriatic skin, we expect that inhibitors against this are highly selective and effective against the disease, and that the risk for side effects is minimal," says Charlotta Enerbäck.

Presently, palliative treatments with vitamin D, cortisone, light and low doses of chemotherapy are used. More recently, some "biological," antibody-based drugs arrived on the market, however they are very expensive and not free from side effects.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by Linköping University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Emman Shubbar, Jenny Vegfors, Maria Carlström, Stina Petersson, Charlotta Enerbäck. Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Research and Treatment, 2011; DOI: 10.1007/s10549-011-1920-5
APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,426

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Follow ScienceDaily on Facebook, Twitter,
and Google:

Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Targeting Cancer in 3D

Radiation therapy requires visualizing exactly where a tumor is located, usually from looking at hundreds of different X-ray , CT or PET scan images.. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: